Gene Expression in Hyperparathyroidism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03044600|
Recruitment Status : Terminated (At the request of the Principal Investigator)
First Posted : February 7, 2017
Last Update Posted : May 23, 2019
- To better define the differences in molecular genetics of parathyroid tumors in patients with MEN1, single gland parathyroid disease in patients less than 50 years old and single gland disease in patients greater than 50 years old.
- To better define the incidence of HRPT2 mutation in young patients with primary hyperparathyroidism and determine whether routine testing in these patients is indicated.
|Condition or disease||Intervention/treatment|
|Parathyroid Disease Hyperparathyroidism||Other: Chart Review Other: HRPT2 Mutation Evaluation|
|Study Type :||Observational|
|Actual Enrollment :||22 participants|
|Official Title:||Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients|
|Actual Study Start Date :||November 7, 2012|
|Actual Primary Completion Date :||October 18, 2017|
|Actual Study Completion Date :||October 18, 2017|
Young MEN1 Negative Group
Participants under 50 years of age who have been diagnosed with MEN1-negative primary hyperparathyroidism.
Other: Chart Review
Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
Other: HRPT2 Mutation Evaluation
Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
- Molecular Genetics of Parathyroid Tumors [ Time Frame: 10 years ]RNA isolated from banked frozen tissues. cDNA microarray prepared using an Illumina array chip. Results analyzed using Ingenuity analysis software to detect 2-fold changes in gene expression. T-statistics used to determine significantly discriminating genes.
- HRPT2 Mutations [ Time Frame: 10 years ]Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03044600
|United States, Texas|
|University of Texas MD Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Nancy D. Perrier, MD||M.D. Anderson Cancer Center|